Last updated: 2026-09-16 12:38:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
LeonaBio, Inc. (LONA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $7.17, with a market capitalisation of $70.38M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.21 to $14.21. This page covers its latest market performance, valuation, price trends and company information.
$70.38M | |
$7.48 | |
$14.21 | |
$4.21 | |
$7.47 | |
22.98K | |
42.79K | |
-- | |
$14.21 | |
$4.21 | |
-- | |
-- |
LeonaBio, Inc. (LONA) is trading at $7.55 in pre-market trading as of 2026-09-15 21:36:00, up 1.06% ($0.08) from the previous close of $7.47
Pre-market trading shows how investors are pricing LONA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, LeonaBio, Inc. (LONA) moved from $7.56 to $7.17, representing a decline of 5.16% ($0.39).
The stock traded between $6.75 and $8.27 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 69.16 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 29.6%
LONA is currently trading at $7.17, placing it 29.6% of the way from its 52-week low of $4.21 to its 52-week high of $14.21. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 19 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of LeonaBio, Inc. (LONA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.